As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody Tecentriq (atezolizumab) for a specific type of previously untreated metastatic bladder cancer.
Two Phase III trials of Genentech (Roche)’s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion (BRVO), showing non-inferiority to Regeneron’s Eylea.
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
The spinal muscular atrophy (SMA) community partnered with the non-profit organization Open Style Lab (OSL) to develop a first-of-its-kind runway show, Double Take, that aims to increase authentic disability representation in the creative sphere and spotlight the need for adaptive design in fashion.
Non-small cell lung cancer (NSCLC) was a hot topic at the recent European Society for Medical Oncology (ESMO) Congress, where several researchers presented landmark findings, many of which are considered to be firsts. Such results portend advances that could significantly improve survival for patients with this common form of cancer.
The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.
Genentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer.
Tuesday morning saw the FDA acceptance of a supplemental New Drug Application (sNDA) and supplemental Biologics License Application (sBLA) for three industry powerhouses.
Q&A with Michael Dunn of Genentech